tradingkey.logo
tradingkey.logo

Pulmonx Corp

LUNG
1.140USD
-0.100-8.06%
Market hours ETQuotes delayed by 15 min
38.67MMarket Cap
LossP/E TTM

Pulmonx Corp

1.140
-0.100-8.06%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Pulmonx Corp

Currency: USD Updated: 2026-03-27

Key Insights

Pulmonx Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 89 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.17.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pulmonx Corp's Score

Industry at a Glance

Industry Ranking
89 / 208
Overall Ranking
217 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Pulmonx Corp Highlights

StrengthsRisks
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 31.78% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 90.50M.
Overvalued
The company’s latest PE is -0.88, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.77M shares, decreasing 23.02% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 4.19K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.32.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
5.167
Target Price
+316.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Pulmonx Corp is 6.57, ranking 138 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 22.60M, representing a year-over-year decrease of 4.91%, while its net profit experienced a year-over-year decrease of 20.87%.

Score

Industry at a Glance

Previous score
6.57
Change
0

Financials

7.78

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.03

Operational Efficiency

5.41

Growth Potential

5.51

Shareholder Returns

7.11

Pulmonx Corp's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Pulmonx Corp is 8.73, ranking 11 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.88, which is 0.00% below the recent high of -0.88 and -937.29% above the recent low of -9.14.

Score

Industry at a Glance

Previous score
8.73
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 89/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Pulmonx Corp is 7.67, ranking 121 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 4.50, with a high of 14.00 and a low of 2.50.

Score

Industry at a Glance

Previous score
7.67
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
5.167
Target Price
+316.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

115
Total
6
Median
9
Average
Company name
Ratings
Analysts
Pulmonx Corp
LUNG
6
Medtronic PLC
MDT
34
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
31
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Pulmonx Corp is 5.85, ranking 172 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.84 and the support level at 0.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
5.75
Change
0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.090
Sell
RSI(14)
31.051
Neutral
STOCH(KDJ)(9,3,3)
4.708
Oversold
ATR(14)
0.117
High Vlolatility
CCI(14)
-118.278
Sell
Williams %R
95.758
Oversold
TRIX(12,20)
-0.667
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
1.282
Sell
MA10
1.387
Sell
MA20
1.543
Sell
MA50
1.583
Sell
MA100
1.797
Sell
MA200
1.943
Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Pulmonx Corp is 7.00, ranking 81 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 79.44%, representing a quarter-over-quarter decrease of 8.80%. The largest institutional shareholder is PRIMECAP Management, holding a total of 4.73M shares, representing 11.19% of shares outstanding, with 16.78% decrease in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
PRIMECAP Management Company
Star Investors
4.96M
-4.03%
Morgan Stanley & Co. LLC
3.45M
+17.41%
The Vanguard Group, Inc.
Star Investors
2.24M
-2.26%
BlackRock Institutional Trust Company, N.A.
2.43M
-0.65%
French (Glendon E III)
2.10M
+131.35%
Sung (Derrick)
1.44M
+496.81%
Silvercrest Asset Management Group LLC
1.26M
+35.86%
DWS Investments UK Limited
1.13M
--
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pulmonx Corp is 1.68, ranking 178 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.19. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
1.68
Change
0
Beta vs S&P 500 index
0.27
VaR
+6.69%
240-Day Maximum Drawdown
+78.37%
240-Day Volatility
+108.58%

Return

Best Daily Return
60 days
+25.47%
120 days
+26.92%
5 years
+32.23%
Worst Daily Return
60 days
-9.90%
120 days
-18.88%
5 years
-60.94%
Sharpe Ratio
60 days
-2.74
120 days
-0.27
5 years
-0.51

Risk Assessment

Maximum Drawdown
240 days
+78.37%
3 years
+92.01%
5 years
+97.43%
Return-to-Drawdown Ratio
240 days
-0.99
3 years
-0.33
5 years
-0.20
Skewness
240 days
-0.52
3 years
+0.03
5 years
-1.30

Volatility

Realised Volatility
240 days
+108.58%
5 years
+86.61%
Standardised True Range
240 days
+17.22%
5 years
+67.55%
Downside Risk-Adjusted Return
120 days
-56.47%
240 days
-56.47%
Maximum Daily Upside Volatility
60 days
+84.77%
Maximum Daily Downside Volatility
60 days
+47.23%

Liquidity

Average Turnover Rate
60 days
+1.58%
120 days
+1.25%
5 years
--
Turnover Deviation
20 days
+131.88%
60 days
+61.01%
120 days
+27.21%

Peer Comparison

Healthcare Equipment & Supplies
Pulmonx Corp
Pulmonx Corp
LUNG
6.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI